Abstract
In the current double-blind study, we examined the impact of depressive symptoms on the efficacy of naltrexone as an adjunct to smoking cessation treatment. Participants were 110 adult nicotine dependent smokers interested in quitting smoking. All subjects received behavioral counseling and nicotine patches. Subjects were randomly assigned to the naltrexone or placebo group. Naltrexone was administered daily starting three days prior to the quit date (25 mg daily) and continued for 8 weeks thereafter (50 mg daily). Smoking cessation status was assessed at the end of treatment and at 24 week follow-up. The efficacy of naltrexone was moderated by depressive symptoms such that naltrexone was related to better quit rates than placebo at higher levels of depressive symptoms. These findings suggest that individual differences in depressive symptoms may be important determinants of clinical response to naltrexone, and may help to clarify discrepancies in prior studies of naltrexone and smoking cessation.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call